Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002754 | 0.82 | HINT1 (0.49) | ADORA2AADORA3ADORA1PGK1PGK2 | |
| SCHEMBL18950662 | 0.82 | HINT1 (0.49) | ADORA2AADORA3ADORA1PGK1PGK2 | |
| SCHEMBL16002733 | 0.81 | KRAS (0.53) | — | |
| SCHEMBL17417840 | 0.81 | KRAS (0.53) | — | |
| SCHEMBL17417839 | 0.81 | KRAS (0.53) | — | |
| SCHEMBL17428139 | 0.80 | ADORA1 (0.59) | ADORA2AADORA3ADORA1SLC29A1 | |
| SCHEMBL17428138 | 0.79 | ADORA1 (0.51) | ADORA2AADORA3ADORA1SLC29A1 | |
| SCHEMBL26631283 | 0.79 | SLC29A1 (0.50) | ADORA2AADORA1SLC29A1 | |
| SCHEMBL26631287 | 0.79 | SLC29A1 (0.50) | ADORA2AADORA1SLC29A1 | |
| SCHEMBL8615037 | 0.78 | ADORA2A (0.55) | ADORA2AADORA3ADORA1SLC29A1PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9463200-B2 | Cell-penetrating oligonucleotides | OLIGOMER SCIENCES AB (SE) | 2016-10-11 | — | — | US | disclosed |
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | ASTRAZENECA AB (SE) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | SLC29A1, SLC29A2, TYMP | ACHE 4725/4885ADORA2A 28/4885ADORA3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.